Oridonin: targeting programmed cell death pathways as an anti-tumour agent

被引:60
|
作者
Liu, Z. [2 ]
Ouyang, L. [3 ,4 ]
Peng, H. [1 ]
Zhang, W. -Z. [2 ]
机构
[1] BeiGene Beijing Co Ltd, Beijing 102206, Peoples R China
[2] Gen Hosp PLA, Dept Hepatobiliary Surg, Beijing 100853, Peoples R China
[3] Sichuan Univ, W China Hosp, State Key Lab Biotherapy, Chengdu 610064, Peoples R China
[4] Sichuan Univ, W China Hosp, Ctr Canc, Chengdu 610064, Peoples R China
关键词
SIGNAL-REGULATED KINASE; FIBROSARCOMA L929 CELLS; CYTOCHROME-C RELEASE; CARCINOMA HELA-CELLS; APOPTOTIC U937 CELLS; NF-KAPPA-B; IN-VITRO; ENHANCED PHAGOCYTOSIS; INDUCED AUTOPHAGY; TRANSDUCTION PATHWAYS;
D O I
10.1111/j.1365-2184.2012.00849.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Oridonin, an active diterpenoid isolated from traditional Chinese herbal medicine, has drawn rising attention for its remarkable apoptosis- and autophagy-inducing activity and relevant molecular mechanisms in cancer therapy. Apoptosis is a well known type of cell death, whereas autophagy can play either pro-survival or pro-death roles in cancer cells. Accumulating evidence has recently revealed relationships between apoptosis and autophagy induced by oridonin; however, molecular mechanisms behind them remain to be discovered. In this review, we focus on highlighting updated research on oridonin-induced cell death signalling pathways implicated in apoptosis and autophagy, in many types of cancer. In addition, we further discuss cross-talk between apoptosis and autophagy induced by oridonin, in cancer. Taken together, these findings open new perspectives for further exploring oridonin as a potential anti-tumour agent targeting apoptosis and autophagy, in future anti-cancer therapeutics.
引用
收藏
页码:499 / 507
页数:9
相关论文
共 50 条
  • [31] Targeting hypoxia to enhance the anti-tumour effect of a stereotactic radiation schedule
    Horsman, M. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S217 - S217
  • [32] Synthesis of phosphinate analogues of the phospholipid anti-tumour agent hexadecylphosphocholine (miltefosine)
    Markoulides, Marios S.
    Regan, Andrew C.
    TETRAHEDRON LETTERS, 2011, 52 (23) : 2954 - 2956
  • [33] Arsenic trioxide as an anti-tumour agent: mechanisms of action and strategies of sensitization
    Sanchez, Yolanda
    Amran, Donna
    de Blas, Elena
    Aller, Patricio
    JOURNAL OF APPLIED BIOMEDICINE, 2010, 8 (04) : 199 - 208
  • [34] Death by a thousand cuts: Granzyme pathways of programmed cell death
    Chowdhury, Dipanjan
    Lieberman, Judy
    ANNUAL REVIEW OF IMMUNOLOGY, 2008, 26 : 389 - 420
  • [35] Microflow Cytometry in Studies of Programmed Tumour Cell Death
    Akagi, Jin
    Takeda, Kazuo
    Fujimura, Yuu
    Matuszek, Anna
    Khoshmanesh, Khashayar
    Wlodkowic, Donald
    26TH EUROPEAN CONFERENCE ON SOLID-STATE TRANSDUCERS, EUROSENSOR 2012, 2012, 47 : 88 - 91
  • [36] Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma
    Goldsmith, KC
    Hogarty, MD
    CANCER LETTERS, 2005, 228 (1-2) : 133 - 141
  • [37] Chemotherapeutic agent gemcitabine may facilitate anti-tumour immune responses by augmenting both tumour visibility and immune cell activation
    Gravett, A. M.
    Copier, J.
    Liu, W. M.
    Cranage, M. P.
    Dalgleish, A. G.
    IMMUNOLOGY, 2013, 140 : 193 - 193
  • [38] Chemotherapeutic Targeting of Cell Death Pathways
    Mansilla, Sylvia
    Llovera, Laia
    Portugal, Jose
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (03) : 226 - 238
  • [39] Significance of Programmed Cell Death Pathways in Neurodegenerative Diseases
    Guo, Dong
    Liu, Zhihao
    Zhou, Jinglin
    Ke, Chongrong
    Li, Daliang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (18)
  • [40] Glutarate regulates T cell metabolism and anti-tumour immunity
    Eleanor Minogue
    Pedro P. Cunha
    Brennan J. Wadsworth
    Guinevere L. Grice
    Shiv K. Sah-Teli
    Rob Hughes
    David Bargiela
    Alessandro Quaranta
    Javier Zurita
    Robin Antrobus
    Pedro Velica
    Laura Barbieri
    Craig E. Wheelock
    Peppi Koivunen
    James A. Nathan
    Iosifina P. Foskolou
    Randall S. Johnson
    Nature Metabolism, 2023, 5 : 1747 - 1764